Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells

Rosalba Minelli, Roberta Cavalli, Leigh Ellis, Piergiorgio Pettazzoni, Francesco Trotta, Eric Ciamporcero, Giuseppina Barrera, Roberto Fantozzi, Chiara Dianzani, Roberto Pili

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Camptothecin (CPT) is a potent DNA Topoisomerase I inhibitor with anti-tumor activity in hematological and solid tumors. However, it did not reach clinical use because of its poor solubility and high degrability. β-Cyclodextrin nanosponge (CN) have been demonstrated to be able to increase the solubility of lipophilic compounds and to protect them from degradation. In the present study, we evaluated whether β-Cyclodextrin nanosponge carriers can overcome CPT chemical disadvantages and improve the in vitro anti-tumor efficacy in the androgen refractory models of prostate cancer DU145 and PC-3 and the androgen sensitive model LNCaP. Camptothecin-loaded β-Cyclodextrin nanosponge (CN-CPT) showed sizes of about 400 nm, spherical shape and a drug loading of 38%. HPLC analysis, performed on the cell pellet after treatment with CN-CPT revealed that CPT concentration increased over time indicating a prolonged release of the drug. Moreover, CN-CPT inhibited Topoisomerase I activity, and induced DNA damage, and cell cycle arrest more effectively than CPT, indicating that the CN-CPT formulation does not affect activity of the drug. Moreover, Annexin V/Propidium Iodide staining showed an induction of cell death at low concentrations that were not effective for CTP. LNCaP cells were less sensitive to CPT than PC-3 and DU145 cells, but CN-CPT still exerted higher anti-proliferative activity and DNA damage ability than CPT. The experiments performed in LNCaP cells demonstrated that CN-CPT treatment inhibited expression of the androgen receptor at doses where CPT was ineffective. Our results demonstrated the higher anti-tumor effectiveness of CN-CPT compare to CPT in prostate cancer cells, supporting the relevance of future studies for the use of the β-Cyclodextrin nanosponge to deliver anticancer drugs in vivo.

Original languageEnglish (US)
Pages (from-to)686-694
Number of pages9
JournalEuropean Journal of Pharmaceutical Sciences
Volume47
Issue number4
DOIs
StatePublished - Nov 20 2012
Externally publishedYes

Keywords

  • Androgen receptor
  • Camptothecin
  • DNA Topoisomerase I
  • DNA damage
  • Prostate cancer
  • β-Cyclodextrin nanosponge

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells'. Together they form a unique fingerprint.

  • Cite this

    Minelli, R., Cavalli, R., Ellis, L., Pettazzoni, P., Trotta, F., Ciamporcero, E., Barrera, G., Fantozzi, R., Dianzani, C., & Pili, R. (2012). Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. European Journal of Pharmaceutical Sciences, 47(4), 686-694. https://doi.org/10.1016/j.ejps.2012.08.003